Seoul Pharma Co., Ltd (KOSDAQ:018680)

Seoul Pharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	18,126	9,949	7,540	6,574	11,728	13,820
Trading Asset Securities	-	-	-	3,090	-	-
Cash & Short-Term Investments	18,126	9,949	7,540	9,664	11,728	13,820
Cash Growth	172.91%	31.94%	-21.98%	-17.61%	-15.14%	-8.24%
Accounts Receivable	4,186	8,470	9,127	5,041	4,925	4,437
Other Receivables	20.43	4,046	338.72	89.52	65.46	33.23
Receivables	4,207	12,516	9,465	5,131	4,990	4,470
Inventory	11,132	11,443	12,104	10,696	9,198	6,466
Prepaid Expenses	23.91	27.28	28.18	28.62	28.89	26.42
Other Current Assets	62.41	79.55	3,120	90.13	66.38	30.4
Total Current Assets	33,551	34,014	32,257	25,609	26,012	24,814
Property, Plant & Equipment	31,640	32,124	33,855	31,330	30,676	34,055
Long-Term Investments	3	3	3	999.4	3	3
Other Intangible Assets	805.25	811.9	809.45	841.72	881.35	865.11
Long-Term Deferred Tax Assets	4,198	4,232	4,142	4,013	4,386	2,070
Other Long-Term Assets	572.83	568.58	552.8	512.48	470.08	443.34
Total Assets	70,770	71,754	71,620	63,305	62,428	62,250

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	2,508	1,951	2,420	2,831	2,995	1,975
Accrued Expenses	4,334	4,839	5,250	4,309	3,933	3,547
Short-Term Debt	5,000	5,000	3,000	-	4,000	18,049
Current Portion of Long-Term Debt	-	-	-	10,000	-	-
Current Portion of Leases	695.96	688.32	666.14	485.16	466.11	463.09
Current Income Taxes Payable	-	-	155.91	-	-	-
Other Current Liabilities	1,531	2,421	2,649	2,907	2,497	4,770
Total Current Liabilities	14,069	14,898	14,141	20,532	13,891	28,805
Long-Term Debt	10,000	10,000	10,000	-	10,000	10,000
Long-Term Leases	1,527	1,704	2,460	470.73	481.28	871.11
Pension & Post-Retirement Benefits	2,892	2,727	3,697	3,083	2,417	3,396
Other Long-Term Liabilities	1,425	1,376	1,149	655.68	216.9	220.46
Total Liabilities	29,912	30,705	31,448	24,741	27,006	43,292

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	5,830	5,830	5,830	5,830	5,830	4,262
Additional Paid-In Capital	29,592	29,592	29,592	29,592	47,247	33,675
Retained Earnings	5,436	5,628	4,750	3,142	-19,414	-20,739
Comprehensive Income & Other	-	0	0	-	1,760	1,760
Shareholders' Equity	40,858	41,050	40,172	38,564	35,422	18,958
Total Liabilities & Equity	70,770	71,754	71,620	63,305	62,428	62,250

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	17,223	17,392	16,126	10,956	14,947	29,383
Net Cash (Debt)	903.78	-7,443	-8,586	-1,292	-3,219	-15,563
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	77.52	-638.40	-736.44	-110.83	-358.47	-1825.71
Filing Date Shares Outstanding	11.66	11.66	11.66	11.66	11.66	8.52
Total Common Shares Outstanding	11.66	11.66	11.66	11.66	11.66	8.52
Working Capital	19,482	19,116	18,116	5,077	12,121	-3,991
Book Value Per Share	3504.32	3520.78	3445.48	3307.58	3038.06	2223.90
Tangible Book Value	40,053	40,238	39,363	37,722	34,540	18,093
Tangible Book Value Per Share	3435.25	3451.14	3376.06	3235.39	2962.47	2122.41
Land	-	5,156	5,156	5,156	5,156	5,156
Buildings	-	27,916	27,916	27,445	27,334	27,334
Machinery	-	25,926	25,420	25,747	24,517	23,201
Construction In Progress	-	332.5	-	40.5	132.85	390.9

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 1, 2026

Data Sources Report a data error